During the past decade, Centro Hospitalar de Setúbal conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 3 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 3 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Hospitalar de Setúbal" #1 sponsor was "Shire" with 3 trials, followed by "Bayer" with 2 trials sponsored, "Assistance Publique - Hôpitaux de Paris" with 1 trials sponsored, "Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Hospitalar de Setúbal" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator and "Canadian VIGOUR Centre" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Centro Hospitalar de Setúbal" are "Ulcerative Colitis" (4 trials), "Acute Stroke" (1 trials), "Arrhythmia" (1 trials), "Atrial Fibrillation" (1 trials) and "Cerebral Infarction" (1 trials). Many other conditions were trialed in "Centro Hospitalar de Setúbal" in a lesser frequency.

Most popular intervention types in "Centro Hospitalar de Setúbal" are "Drug" (10 trials), "Device" (3 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Ontamalimab" (2 trials), "25 mg Ontamalimab" (1 trials), "75 mg Ontamalimab" (1 trials) and "Alteplase" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro Hospitalar de Setúbal" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Centro Hospitalar de Setúbal". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Centro Hospitalar de Setúbal, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Hospitalar de Setúbal, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".